Dihydroergotamine

Contraindicated

Dihydroergotamine Dobutamine Increased risk of elevation of blood pressure Details Dihydroergotamine Dopamine Increased risk of elevation of blood pressure Details Dihydroergotamine Ketoconazole Topical Extina® Foam Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Letermovir Injection Prevymis Increased ergot alkaloids exposure and an increased risk of ergotism Details Dihydroergotamine Methylergonovine Methergine An increased risk of ergotism Details

Major

Dihydroergotamine Abametapir Explained Increased exposure of CYP3A4 substrate Details Dihydroergotamine Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Dihydroergotamine Azithromycin AzaSite An increased risk of acute ergot toxicity (ergotism) Details Dihydroergotamine Clotrimazole Aardora Anti-Fungal Maximum Strength Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Clotrimazole Lozenge Mycelex® Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Clotrimazole Topical Cruex Antifungal Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Clotrimazole Vaginal Gyne-Lotrimin 3® Cream Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Dihydroergotamine Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Dihydroergotamine Lenacapavir Injection Sunlenca Increased dihydroergotamine exposure Details Dihydroergotamine Lenacapavir Oral Sunlenca Increased dihydroergotamine exposure Details Dihydroergotamine Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Dihydroergotamine Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Dihydroergotamine Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Moderate

Dihydroergotamine Sertraline Explained An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Metronidazole Flagyl Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Metronidazole Injection Flagyl Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Metronidazole Topical MetroCream® Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Metronidazole Vaginal MetroGel® Vaginal Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nitroglycerin Gonitro Dihydroergotamine toxicity (peripheral ischemia, paresthesias, nausea, vomiting) Details Dihydroergotamine Nitroglycerin Spray Nitrolingual Dihydroergotamine toxicity (peripheral ischemia, paresthesias, nausea, vomiting) Details Dihydroergotamine Nitroglycerin Sublingual Nitrostat Dihydroergotamine toxicity (peripheral ischemia, paresthesias, nausea, vomiting) Details Dihydroergotamine Nitroglycerin Topical Nitro-Bid Dihydroergotamine toxicity (peripheral ischemia, paresthesias, nausea, vomiting) Details Dihydroergotamine Nitroglycerin Transdermal Patch Minitran® Patch Dihydroergotamine toxicity (peripheral ischemia, paresthesias, nausea, vomiting) Details